Groundbreaking Alfred Block

State-of-the-art R&D facilities for powerful drug development

We, at Tiefenbacher Group, go beyond R&D and manufacturing of pharmaceuticals with a commitment to quality, safety, and reliability that is anchored in everything we do. We are therefore pleased to announce that the #foundation stone for one of our new Tiefenbacher Laboratories buildings has now been laid. The new development block “Alfred”, named after our founder Alfred E. Tiefenbacher, will provide 3360 m² over three floors of space for our new product development lab, analytical lab as well as administrative offices and a canteen for the employees. The building complex is an important extension to the recently inaugurated development block for highly potent drugs. It will take shape over the next few months and will be ready to be fully operational in about one year.

This investment follows Tiefenbacher Group’s strategy to strengthen its position as a global, fully integrated pharmaceutical company. With Tiefenbacher Laboratories, we own a state-of-the-art R&D and manufacturing site located in Hyderabad, India, for developing and producing high-quality pharmaceuticals. The facilities are equipped with the most modern technologies and software and are subject to the strictest international quality standards. We look forward to sharing more updates on the progress in the coming months.

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email